Definium says its LSD drug notched another Phase 3 win in anxiety disorder

Definium Therapeutics reported positive results from its third Phase 3 clinical trial this year for its oral LSD drug candidate DT120 targeting anxiety disorder, advancing toward potential regulatory approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.